105 related articles for article (PubMed ID: 38871039)
1. Can Semaglutide Offer Hope for Patients with Obesity-Related Heart Failure?
Olatunji G; Aderinto N; Kokori E; Ogieuhi IJ; Abraham IC; Olanisa O; Nebuwa C; Awoyinfa M; Ajimotokan O; Ajayi JO; Rao NN; Temidayo AO; Napoleon T; Samuel O; Ezeano C
Curr Probl Cardiol; 2024 Jun; ():102697. PubMed ID: 38871039
[TBL] [Abstract][Full Text] [Related]
2. Semaglutide in Heart Failure With Preserved Ejection Fraction: Exploring Recent Evidence in Therapeutic Potential for the Obese Population.
Kusayev J; Levy Y; Weininger D; Frishman WH; Aronow WS
Cardiol Rev; 2024 May; ():. PubMed ID: 38757954
[TBL] [Abstract][Full Text] [Related]
3. Semaglutide and Diuretic Use in Obesity-Related Heart Failure with Preserved Ejection Fraction: A Pooled Analysis of the STEP-HFpEF and STEP-HFpEF-DM trials.
Shah SJ; Sharma K; Borlaug BA; Butler J; Davies M; Kitzman DW; Petrie MC; Verma S; Patel S; Chinnakondepalli KM; Einfeldt MN; Jensen TJ; Rasmussen S; Asleh R; Ben-Gal T; Kosiborod MN
Eur Heart J; 2024 May; ():. PubMed ID: 38739118
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of semaglutide in patients with heart failure with preserved ejection fraction and obesity.
Rehman A; Saidullah S; Asad M; Gondal UR; Ashraf A; Khan MF; Akhtar W; Mehmoodi A; Malik J
Clin Cardiol; 2024 May; 47(5):e24283. PubMed ID: 38767042
[TBL] [Abstract][Full Text] [Related]
5. Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients With Heart Failure With Preserved Ejection Fraction and Obesity: A Prespecified Analysis of the STEP-HFpEF Trial.
Kosiborod MN; Verma S; Borlaug BA; Butler J; Davies MJ; Jon Jensen T; Rasmussen S; Erlang Marstrand P; Petrie MC; Shah SJ; Ito H; Schou M; Melenovský V; Abhayaratna W; Kitzman DW;
Circulation; 2024 Jan; 149(3):204-216. PubMed ID: 37952180
[TBL] [Abstract][Full Text] [Related]
6. Obesity, heart failure with preserved ejection fraction, and the role of glucagon-like peptide-1 receptor agonists.
Cimino G; Vaduganathan M; Lombardi CM; Pagnesi M; Vizzardi E; Tomasoni D; Adamo M; Metra M; Inciardi RM
ESC Heart Fail; 2024 Apr; 11(2):649-661. PubMed ID: 38093506
[TBL] [Abstract][Full Text] [Related]
7. Targeting obesity for therapeutic intervention in heart failure patients.
Sato R; von Haehling S
Expert Rev Cardiovasc Ther; 2024 Jun; 22(6):217-230. PubMed ID: 38864827
[TBL] [Abstract][Full Text] [Related]
8. The Cardioprotective Effects of Semaglutide Exceed Those of Dietary Weight Loss in Mice With HFpEF.
Withaar C; Meems LMG; Nollet EE; Schouten EM; Schroeder MA; Knudsen LB; Niss K; Madsen CT; Hoegl A; Mazzoni G; van der Velden J; Lam CSP; Silljé HHW; de Boer RA
JACC Basic Transl Sci; 2023 Oct; 8(10):1298-1314. PubMed ID: 38094687
[TBL] [Abstract][Full Text] [Related]
9. Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review.
Feier CVI; Vonica RC; Faur AM; Streinu DR; Muntean C
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673931
[TBL] [Abstract][Full Text] [Related]
10. Semaglutide and NT-proBNP in Obesity-Related HFpEF: Insights From the STEP-HFpEF Program.
Petrie MC; Borlaug BA; Butler J; Davies MJ; Kitzman DW; Shah SJ; Verma S; Jensen TJ; Einfeldt MN; Liisberg K; Perna E; Sharma K; Ezekowitz JA; Fu M; Melenovský V; Ito H; Lelonek M; Kosiborod MN;
J Am Coll Cardiol; 2024 May; ():. PubMed ID: 38819334
[TBL] [Abstract][Full Text] [Related]
11. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.
Kosiborod MN; Abildstrøm SZ; Borlaug BA; Butler J; Rasmussen S; Davies M; Hovingh GK; Kitzman DW; Lindegaard ML; Møller DV; Shah SJ; Treppendahl MB; Verma S; Abhayaratna W; Ahmed FZ; Chopra V; Ezekowitz J; Fu M; Ito H; Lelonek M; Melenovsky V; Merkely B; Núñez J; Perna E; Schou M; Senni M; Sharma K; Van der Meer P; von Lewinski D; Wolf D; Petrie MC;
N Engl J Med; 2023 Sep; 389(12):1069-1084. PubMed ID: 37622681
[TBL] [Abstract][Full Text] [Related]
12. Design and Baseline Characteristics of STEP-HFpEF Program Evaluating Semaglutide in Patients With Obesity HFpEF Phenotype.
Kosiborod MN; Abildstrøm SZ; Borlaug BA; Butler J; Christensen L; Davies M; Hovingh KG; Kitzman DW; Lindegaard ML; Møller DV; Shah SJ; Treppendahl MB; Verma S; Petrie MC
JACC Heart Fail; 2023 Aug; 11(8 Pt 1):1000-1010. PubMed ID: 37294245
[TBL] [Abstract][Full Text] [Related]
13. Role of glucagon-like peptide-1 agonists in obesity and heart failure with preserved ejection fraction.
Temporelli PL
Eur Heart J Suppl; 2024 Apr; 26(Suppl 1):i127-i130. PubMed ID: 38867875
[TBL] [Abstract][Full Text] [Related]
14. Beyond Weight Loss: the Emerging Role of Incretin-Based Treatments in Cardiometabolic HFpEF.
Capone F; Nambiar N; Schiattarella GG
Curr Opin Cardiol; 2024 May; 39(3):148-153. PubMed ID: 38294187
[TBL] [Abstract][Full Text] [Related]
15. Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes.
Kosiborod MN; Petrie MC; Borlaug BA; Butler J; Davies MJ; Hovingh GK; Kitzman DW; Møller DV; Treppendahl MB; Verma S; Jensen TJ; Liisberg K; Lindegaard ML; Abhayaratna W; Ahmed FZ; Ben-Gal T; Chopra V; Ezekowitz JA; Fu M; Ito H; Lelonek M; Melenovský V; Merkely B; Núñez J; Perna E; Schou M; Senni M; Sharma K; van der Meer P; Von Lewinski D; Wolf D; Shah SJ;
N Engl J Med; 2024 Apr; 390(15):1394-1407. PubMed ID: 38587233
[TBL] [Abstract][Full Text] [Related]
16. Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial.
Borlaug BA; Kitzman DW; Davies MJ; Rasmussen S; Barros E; Butler J; Einfeldt MN; Hovingh GK; Møller DV; Petrie MC; Shah SJ; Verma S; Abhayaratna W; Ahmed FZ; Chopra V; Ezekowitz J; Fu M; Ito H; Lelonek M; Melenovsky V; Núñez J; Perna E; Schou M; Senni M; van der Meer P; Von Lewinski D; Wolf D; Kosiborod MN
Nat Med; 2023 Sep; 29(9):2358-2365. PubMed ID: 37635157
[TBL] [Abstract][Full Text] [Related]
17. Semaglutide once-weekly: improved efficacy with a new safety warning.
Coon SA; Crannage EF; Kerwin LC; Guyton JE
Expert Rev Clin Pharmacol; 2018 Nov; 11(11):1061-1072. PubMed ID: 30296182
[TBL] [Abstract][Full Text] [Related]
18. Association of semaglutide with reduced incidence and relapse of cannabis use disorder in real-world populations: a retrospective cohort study.
Wang W; Volkow ND; Berger NA; Davis PB; Kaelber DC; Xu R
Mol Psychiatry; 2024 Mar; ():. PubMed ID: 38486046
[TBL] [Abstract][Full Text] [Related]
19. Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes considered for injectable GLP-1 receptor agonist therapy or currently on insulin therapy.
Wright EE; Aroda VR
Postgrad Med; 2020 Nov; 132(sup2):26-36. PubMed ID: 32815423
[TBL] [Abstract][Full Text] [Related]
20. Clinical Impact of Semaglutide, a Glucagon-Like Peptide-1 Receptor Agonist, on Obesity Management: A Review.
Alorfi NM; Algarni AS
Clin Pharmacol; 2022; 14():61-67. PubMed ID: 35958046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
